Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04513652 · ClinicalTrials.gov registry record · Phase 3
A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution
A Phase 3 study, sponsored by American Genomics.
- Completed
- Registry status
- Phase 3
- Development phase
- 120
- Enrollment target
NCT04513652: Completed Phase 3 study, sponsored by American Genomics.
NCT04513652 is a Phase 3 study that has completed, run by American Genomics. The registered enrollment target is 120 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (84% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04513652, a Phase 3 study, has completed, sponsored by American Genomics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 120 participants
- Enrollment target
Study Summary
This is a Phase 3, randomized, placebo-controlled, double masked, parallel design study in healthy subjects performed in the US. It is designed to evaluate the safety and anesthetic efficacy of AG-920 Sterile Topical Ophthalmic Solution.
Primary Outcome
Immediately following EACH pinch test, subjects will be asked "Was that painful" "Yes" or "NO."
Interventions
- DRUG Placebo
- DRUG AG-920
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2020-09-03 |
| Est. Completion | 2020-12-17 |
| Phase | Phase 3 |
What the finished NCT04513652 record still lists
NCT04513652 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (84% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04513652 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04513652 about?
NCT04513652 is a clinical study titled "A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution". This is a Phase 3, randomized, placebo-controlled, double masked, parallel design study in healthy subjects performed in the US. It is designed to evaluate the safety and anesthetic efficacy of AG-920 Sterile Topical Ophthalmic Solution.
What is the current status of trial NCT04513652?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 120 participants. The study started on 2020-09-03. Estimated completion is 2020-12-17.
What interventions are being tested in trial NCT04513652?
The interventions under investigation include: Placebo (DRUG), AG-920 (DRUG).
Who is sponsoring clinical trial NCT04513652?
This trial is sponsored by American Genomics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04513652's enrollment target sits among peer trials
120 1619th of 2000 higher than 361 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI